New Type 2 Diabetes Treatments: GLP-1 Drugs, SGLT2 Inhibitors, and What’s Changed

Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider about treatment options.

Type 2 diabetes treatment has changed more in the past ten years than in the preceding four decades. New drug classes, better understanding of cardiovascular and kidney risks, and a growing recognition that remission is achievable for many people have all transformed what a diabetes diagnosis means in practice.

GLP-1 Receptor Agonists: The Most Significant Advance

GLP-1 receptor agonists — including semaglutide (Ozempic, Wegovy), liraglutide (Victoza), dulaglutide (Trulicity), and tirzepatide (Mounjaro) — have emerged as the most transformative drug class in Type 2 diabetes management. Their effects go well beyond blood sugar:

• Weight loss: 5–22% of body weight depending on the specific drug and dose
• Cardiovascular protection: multiple large trials (LEADER, SUSTAIN-6, REWIND) show reduced rates of heart attack, stroke, and cardiovascular death
• Kidney protection: emerging evidence supports GLP-1 drugs’ role in slowing chronic kidney disease progression
• A1C reduction: 1.0–2.3% depending on drug and dose

The ADA’s pharmacologic treatment guidelines now recommend GLP-1 drugs — particularly for people with established cardiovascular disease or high cardiovascular risk — independent of A1C level.

SGLT2 Inhibitors: Heart and Kidney Specialists

SGLT2 inhibitors (empagliflozin/Jardiance, dapagliflozin/Farxiga, canagliflozin/Invokana) work by blocking glucose reabsorption in the kidneys, causing excess glucose to be excreted in urine. What makes them remarkable is their organ-protective effects:

• The EMPA-REG OUTCOME trial found empagliflozin reduced hospitalization for heart failure by 35% and cardiovascular death by 38%
• CREDENCE trial: canagliflozin reduced risk of kidney failure by 30% in people with diabetic kidney disease
• DAPA-CKD trial: dapagliflozin showed kidney protection even in people without diabetes

These aren’t marginal benefits — SGLT2 inhibitors are now considered first-line therapy alongside metformin for people with Type 2 diabetes who also have heart failure or chronic kidney disease, regardless of blood sugar levels.

Tirzepatide: Dual-Receptor Breakthrough

Tirzepatide (Mounjaro), approved by the FDA in 2022, activates both GLP-1 and GIP receptors — the first drug of its class. In the SURPASS clinical trial program, it produced:

• A1C reductions of up to 2.3% — greater than any previous diabetes drug
• Weight loss of up to 11 kg (24 lbs) in people with Type 2 diabetes
• 52% of participants achieved A1C below 5.7% (normal range) at the highest dose

Oral Semaglutide: GLP-1 Benefits Without Injections

Oral semaglutide (Rybelsus) was the first oral GLP-1 receptor agonist approved for Type 2 diabetes. While it produces slightly less weight loss than injectable semaglutide, it offers the cardiovascular and glycemic benefits of the GLP-1 drug class in pill form — a significant convenience advantage for patients who prefer to avoid injections. The FDA’s approval announcement summarizes the clinical evidence.

Advances in Insulin Therapy

For people who require insulin, newer formulations have improved the experience considerably:

• Ultra-long-acting insulins (degludec/Tresiba) — stable action for 42+ hours; more forgiving with missed or shifted dose timing
• Concentrated insulins (U-200, U-300, U-500) — smaller injection volumes for people requiring high doses
• Biosimilar insulins — significantly lower cost alternatives to brand-name insulins; FDA-approved versions of glargine and lispro are now widely available

Metabolic Surgery: Remission for Eligible Patients

For people with a BMI ≥ 35 and Type 2 diabetes (or BMI ≥ 30 with poorly controlled disease), bariatric surgery produces diabetes remission in 50–80% of patients — far exceeding any medication. The ADA formally includes metabolic surgery as a recommended treatment option, not a last resort. Long-term data from multiple trials show remission rates are durable at 5 and 10 years for many patients.

Continuous Glucose Monitors and Automated Insulin Delivery

Technology-based interventions have transformed diabetes monitoring. CGMs provide real-time glucose data without fingersticks. Automated insulin delivery (AID) systems pair CGMs with smart insulin pumps that adjust basal insulin automatically — producing better time-in-range with less manual intervention. Both are now covered by Medicare for people who qualify.

Related Reading

• Best Treatment Options for Type 2 Diabetes: Medications, Lifestyle, and Surgery
• Tirzepatide for Type 2 Diabetes: How It Compares to Other GLP-1 Drugs
• Continuous Glucose Monitors (CGMs) for Type 2 Diabetes
• Type 2 Diabetes ESSENCE Trial Findings: Semaglutide Results

keithsurveys2@gmail.com

Keith Williams is the creator of ABCs of A1C, an educational resource focused on blood sugar control and Type 2 diabetes awareness. His work focuses on translating complex metabolic and diabetes research into practical lifestyle information that readers can understand and apply in daily life.

See Full Bio